An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 04 Jan 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms VEGF Liver 100
- Sponsors Pfizer
- 14 Nov 2019 Status changed from active, no longer recruiting to completed.
- 06 Jul 2019 Planned End Date changed from 7 Oct 2019 to 14 Jan 2020.
- 06 Jul 2019 Planned primary completion date changed from 13 Aug 2019 to 15 Aug 2019.